Read by QxMD icon Read

Clinical Trial And Colorectal Cancer

Shingo Kato, Takuo Hayashi, Yoshiyuki Suehara, Haruka Hamanoue, Shoji Yamanaka, Yasushi Ichikawa, Takuma Higurashi, Kenichi Ohashi, Shigeo Yamaguchi, Yumi Nozaki, Yasuhisa Terao, Tsuyoshi Saito
Background: Application of next-generation DNA sequencing (NGS) has recently become increasingly common in the field of clinical oncology in several countries around the world. In Japan also, a system for applying NGS to routine clinical practice is gradually being established. During this process, we introduced in Japan the tumor-profiling MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) assay. Methods: We present here our initial experience with the use of MSK-IMPACT in 68 patients selected from two institutions in Japan between June 2016 and October 2017...
December 12, 2018: Japanese Journal of Clinical Oncology
Xiaojing Ouyang, Qingfeng Li, Mengjing Shi, Dongsheng Niu, Wenjing Song, Qinggong Nian, Xiangda Li, Zhonghui Ding, Xianyin Ai, Jian Wang
PURPOSE: Postoperative infection has seriously affected the prognosis of cancer patients, while probiotics have been increasingly used to prevent postoperative infection in clinical practice. This study aimed to evaluate the preventive effect of probiotics on infection after colorectal cancer (CRC) surgery. METHODS: Related clinical trial reports were collected from Pubmed, Embase, Cochrane Library as well as China National Knowledge Infrastructure (CNKI) databases...
December 11, 2018: International Journal of Colorectal Disease
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Colorectal cancer (CRC) is known as the third most common and fourth leading cancer associated death worldwide. The occurrence of metastasis has remained as a critical challenge in CRC, so that distant metastasis (mostly to the liver) has been manifested in about 20%-25% of patients. Several screening approaches have introduced for detecting CRC in different stages particularly in early stages. The standard treatments for CRC are surgery, chemotherapy and radiotherapy, in alone or combination. Immunotherapy is a set of novel approaches with the aim of remodeling the immune system battle with metastatic cancer cells, such as immunomodulatory monoclonal antibodies (immune checkpoint inhibitors), adoptive cell transfer (ACT) and cancer vaccine...
December 9, 2018: Journal of Cellular Biochemistry
Changwen Jing, Huizi Li, Yuanyuan Du, Haixia Cao, Siwen Liu, Zhuo Wang, Rong Ma, Jifeng Feng, Jianzhong Wu
Mitogen‑activated protein kinase kinase (MEK) small molecule inhibitors have been investigated in preclinical or clinical trials for the treatment of cancer. In the present study the genetic test results of 120 patients with colorectal cancer (CRC) were screened and the mutation rate of MEK1 was identified to be 1.67%. MEK inhibition by U0126 significantly decreased the growth of SW48 cells that harbored the MEK1 Q56P mutation, although it did not evidently affect the growth of NCI‑H508 cells with MEK1 wild‑type...
December 7, 2018: Molecular Medicine Reports
Qian Feng, Haojia Wang, Jiaying Pang, Liyan Ji, Jiada Han, Ying Wang, Xiaoxiao Qi, Zhongqiu Liu, Linlin Lu
The tumor suppressor protein p53 plays an important role in the development and progression of colon cancer, and the subcellular organelle localization directly affects its function. Wogonin (5,7-dihydroxy-8-methoxyflavone), a mono-flavonoid extracted from root of Scutellaria baicalensis Georgi , possesses acceptable toxicity and has been used in colorectal cancer (CRC) chemoprevention in pre-clinical trials by oncologist. However, the underlying anti-colon cancer mechanisms of wogonin are not yet fully understood...
2018: Frontiers in Pharmacology
Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Flavia Pagan, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi
Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome. Patients and methods: Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B...
2018: Cancer Management and Research
Aziz Zaanan, Julien Taieb
The MSI phenotype in colon cancer is a good prognostic factor, with an impact probably more pronounced for stage II than stage III tumor. This survival advantage may be related to the tumor-infiltrating lymphocytes observed in MSI tumors, thus explaining the existence of a probably more effective anti-tumor immune response. In addition, the MSI status would also be a biomarker able to predict the lack of efficacy of adjuvant 5-fluorouracil (5FU) chemotherapy. In contrast, as observed in MSS colon cancer, the MSI tumors would have a survival benefit with the addition of oxaliplatin to adjuvant 5FU chemotherapy...
December 4, 2018: Bulletin du Cancer
Yihong Liu, Brian H May, Anthony Lin Zhang, Xinfeng Guo, Chuanjian Lu, Charlie Changli Xue, Haibo Zhang
OBJECTIVES: To assess the clinical evidence for integrative herbal medicine therapy in the management of chemotherapy-induced peripheral neuropathy (CIPN) and hand-foot syndrome (HFS) resulting from treatments for colorectal cancer (CRC). DESIGN: Randomized controlled trials (RCTs) were identified from major English and Chinese databases. Participants had been diagnosed with CRC by pathology and had received or were undergoing chemotherapy. Interventions included herbal medicines administered orally or topically...
December 10, 2018: Integrative Cancer Therapies
Xiangsheng Liu, Jinhong Jiang, Ryan Chan, Ying Ji, Jianqin Lu, Yu-Pei Liao, Michael Okene, Joshua Lin, Paulina Lin, Chong Hyun Chang, Xiang Wang, Ivanna Tang, Emily Zheng, Waveley Qiu, Zev A Wainberg, Andre E Nel, Huan Meng
Irinotecan is a key chemotherapeutic agent for the treatment of colorectal (CRC) and pancreatic (PDAC) cancer. Because of a high incidence of bone marrow and gastrointestinal (GI) toxicity, Onivyde (a liposome) was introduced to provide encapsulated irinotecan (Ir) delivery in PDAC patients. While there is an ongoing clinical trial (NCT02551991) to investigate the use of Onivyde as a first-line option to replace irinotecan in FOLFIRINOX, the liposomal formulation is currently prescribed as a second-line treatment option (in combination with 5-fluorouracil and leucovorin) for patients with metastatic PDAC who failed gemcitabine therapy...
December 11, 2018: ACS Nano
Yusuke Suwa, Jun Watanabe, Mitsuyoshi Ota, Shinsuke Suzuki, Hirokazu Suwa, Kazuteru Watanabe, Shuji Saito, Koutaro Nagamine, Masashi Momiyama, Atsushi Ishibe, Yusuke Saigusa, Takeharu Yamanaka, Itaru Endo
PURPOSE: Capeox is widely used as an adjuvant chemotherapy regimen of colorectal cancer that does not require central vein catheter insertion. However, oxaliplatin-related vascular pain with peripheral administration is a major adverse event. We assessed the preventive effect of Celecoxib on oxaliplatin-related vascular pain. METHODS: A multicenter study of the Yokohama Clinical Oncology Group (YCOG) in Japan. This study was an open label, randomized non-comparative phase II study between Capeox without Celecoxib (C+ Group) and with it (C- group)...
December 6, 2018: Cancer Chemotherapy and Pharmacology
Neda Yaghoubi, Arash Soltani, Kiarash Ghazvini, Seyed Mahdi Hassanian, Seyed Isaac Hashemy
Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically been notable worldwide and many attempts have been made to raise the overall survival of CRC patients. Immune response has long been a question of great interest in a wide range of fields such as cancer therapies and anti-tumor immunity through checkpoint inhibitors, specifically anti PD-1/ PD-L1 interaction, is a new line of research for treatment of CRC patients. Following the successful development of anti-PD-1 for melanoma, renal cell carcinoma, and non-small cell lung cancer, several clinical trials have been conducted on monoclonal antibodies (MAbs) against PD-1 in CRC...
December 3, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Marilena Petrera, Laura Paleari, Matteo Clavarezza, Matteo Puntoni, Silvia Caviglia, Irene Maria Briata, Massimo Oppezzi, Eva Mihajlovic Mislej, Borut Stabuc, Michael Gnant, Thomas Bachleitner-Hofmann, Wilfried Roth, Dominique Scherer, Walter-E Haefeli, Cornelia M Ulrich, Andrea DeCensi
BACKGROUND: Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases. Metformin has also been associated with decreased colon adenoma recurrence in clinical trials and lower CRC incidence and mortality in epidemiological studies in diabetics. While both drugs have been tested as single agents, their combination has not been tested in cancer prevention trials...
December 4, 2018: BMC Cancer
Prithy C Martis, Atira T Dudley, Melissa A Bemrose, Hunter L Gazda, Barry H Smith, Lawrence S Gazda
BACKGROUND: Agarose encapsulated murine renal adenocarcinoma cells (RENCA macrobeads) are currently being investigated in clinical trials as a treatment for therapy-resistant metastatic colorectal cancer. We have previously demonstrated the capacity of RENCA macrobeads to produce diffusible substances that markedly inhibit the proliferation of epithelial-derived tumor cells outside the macrobead environment. This study examined the molecular mechanisms underlying the observed inhibition in targeted tumor cells exposed to RENCA macrobeads...
December 4, 2018: BMC Cancer
Anna La Salvia, Victoria Lopez-Gomez, Rocio Garcia-Carbonero
Colorectal cancer (CRC) is one of the most common malignant tumors; it is a focus of research globally, but the identification of clinically actionable oncogenic drivers remains elusive. HER2 activation is present in approximately 5% of CRC and has acquired resistance to EGFR-targeted therapy. Early clinical trials suggest an emerging role for personalized HER2-targeted therapy in a subset of metastatic CRC. Areas covered: This manuscript reviews the relevance of HER2 activation in CRC and its potential role as a target for therapy...
December 4, 2018: Expert Opinion on Investigational Drugs
Gaurav Goel
Colorectal cancer (CRC) is a major public health problem, both in the USA and globally. Over the past 20 years, significant advances have been made in the treatment of patients with metastatic CRC (mCRC). Recent efforts in the field of biomarkers have focused on the development of molecular diagnostics to define the subset of patients with mCRC that is likely to derive most benefit from anti-EGFR therapy. Herein, we review the recent advancements in molecular stratification of CRC and the role of current as well as emerging biomarkers in this disease...
2018: Cancer Management and Research
Yuhong Xie, Xiaojie Wang, Zhifen Chen, Pan Chi, Guoxian Guan, Huiming Lin, Xingrong Lu, Ying Huang, Zhengqiong Wang, Mingxing Wang, Jie Chen, Xiuying Li, Min Wang, Xuezhen Zheng, Ximei Zheng, Ran Li, Qianqian Lin
OBJECTIVE: To investigate the efficacy and safety of the bladder training in male patients before urinary catheter removal after mid-low rectal cancer surgery. METHODS: This was a prospective, open, randomized controlled study. INCLUSION CRITERIA: male patients; pathologically diagnosed as mid-low rectal adenocarcinoma; distance from tumor lower edge to anal margin ≤10 cm; standard radical surgery for rectal cancer, including intestinal resection and regional lymph node dissection...
November 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
Jiagang Han, Zhenjun Wang, Yong Dai, Xiaorong Li, Qun Qian, Guiying Wang, Guanghui Wei, Weigen Zeng, Liangang Ma, Baocheng Zhao, Yanlei Wang, Kaiyan Yang, Zhao Ding, Xuhua Hu
OBJECTIVE: To evaluate the safety and feasibility of neoadjuvant chemotherapy prior elective surgery following self-expanding metallic stents (SEMS) for complete obstructive left hemicolon cancer. METHODS: This prospective, multicenter, open-labelled trial was approved by the Ethics Committee of Beijing Chaoyang Hospital, Capital Medical University(2016-ke-161-1) and registered in (NCT02972541). INCLUSION CRITERIA: (1)age between 18 and 75 years old;(2) adenocarcinoma confirmed by pathology;(3) left hemicolon cancer confirmed by clinical manifestations and imaging examinations with the distance to anal verge > 15 cm; (4) resectable cancer evaluated by imaging examination without distant metastasis; (5) Eastern Cooperative Oncology Group (ECOG) score ≤ 1 or Karnofsky Performance Scale (KPS) > 70, indicating tolerance of neoadjuvant chemotherapy and operation; (6) absence of chemotherapy or radiotherapy within past six months; (7) bone marrow system and hepatorenal function: hemoglobin ≥ 90 g/L, neutrophil ≥ 1...
November 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
Oğuzhan Çelik, Cem Çil, Bülent Özlek, Eda Özlek, Volkan Doğan, Özcan Başaran, Erkan Demirci, Lütfü Bekar, Macit Kalçık, Osman Karaarslan, Mücahit Yetim, Tolga Doğan, Vahit Demir, Sedat Kalkan, Buğra Özkan, Şıho Hidayet, Gökay Taylan, Zafer Küçüksu, Yunus Çelik, Süleyman Çağan Efe, Onur Aslan, Murat Biteker
OBJECTIVE: The aim of this study was to describe the current status of aspirin use and the demographic characteristics of patients on aspirin for primary and secondary prevention of cardiovascular diseases. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) trial was a multicenter, cross-sectional, and observational study conducted in Turkey. The study was planned to include 5000 patients from 14 cities in Turkey...
December 2018: Anatolian Journal of Cardiology
Scott K Sherman, Joel J Lange, Fadi S Dahdaleh, Rahul Rajeev, T Clark Gamblin, Blase N Polite, Kiran K Turaga
Importance: Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment's cost justifies its benefits has not been evaluated in the United States. Objective: This study sought to determine the influence of capecitabine and bevacizumab drug prices on cost-effectiveness from a Medicare payer's perspective...
November 29, 2018: JAMA Oncology
Teodora Costea, Ariana Hudiță, Oana-Alina Ciolac, Bianca Gălățeanu, Octav Ginghină, Marieta Costache, Constanța Ganea, Maria-Magdalena Mocanu
Colorectal cancer is one of the leading causes of death, and the third most diagnosed type of cancer, worldwide. It is most common amongst men and women over 50 years old. Risk factors include smoking, alcohol, diet, physical inactivity, genetics, alterations in gut microbiota, and associated pathologies (diabetes, obesity, chronic inflammatory bowel diseases). This review will discuss, in detail, the chemopreventive properties of some dietary compounds (phenolic compounds, carotenoids, iridoids, nitrogen compounds, organosulfur compounds, phytosterols, essential oil compounds, polyunsaturated fatty acids and dietary fiber) against colorectal cancer...
November 28, 2018: International Journal of Molecular Sciences
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"